Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis
François Chasset, Jean‐David Bouaziz, N. Costedoat‐Chalumeau, et al.
British Journal of Dermatology (2017) Vol. 177, Iss. 1, pp. 188-196
Closed Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Antonis Fanouriakis, Myrto Kostopoulou, Alessia Alunno, et al.
Annals of the Rheumatic Diseases (2019) Vol. 78, Iss. 6, pp. 736-745
Open Access | Times Cited: 1706
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Antonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen, et al.
Annals of the Rheumatic Diseases (2023) Vol. 83, Iss. 1, pp. 15-29
Open Access | Times Cited: 368
Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases
Hideyuki Ujiie, David Rosmarin, Michael P. Schön, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 112
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus
Victoria P. Werth, Richard Furie, Juanita Romero‐Díaz, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 4, pp. 321-331
Open Access | Times Cited: 80
The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand?
Matteo Piga, Laurent Arnaud
Journal of Clinical Medicine (2021) Vol. 10, Iss. 2, pp. 243-243
Open Access | Times Cited: 76
Cutaneous lupus erythematosus: a review of etiopathogenic, clinical, diagnostic and therapeutic aspects
Everton Carlos Siviero do Vale, Lucas Campos Garcia
Anais Brasileiros de Dermatologia (2023) Vol. 98, Iss. 3, pp. 355-372
Open Access | Times Cited: 31
Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis
François Chasset, T. Tounsi, E. Cesbron, et al.
Journal of the American Academy of Dermatology (2017) Vol. 78, Iss. 2, pp. 342-350.e4
Closed Access | Times Cited: 67
Cutaneous Manifestations of “Lupus”: Systemic Lupus Erythematosus and Beyond
Elizabeth Cooper, Catherine Pisano, Samantha C. Shapiro
International Journal of Rheumatology (2021) Vol. 2021, pp. 1-19
Open Access | Times Cited: 45
Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?
Alina Dima, Ciprian Jurcuț, Laurent Arnaud
Joint Bone Spine (2021) Vol. 88, Iss. 3, pp. 105143-105143
Closed Access | Times Cited: 38
Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE
Aaron Bao, Michelle Petri, Andrea Fava, et al.
Lupus Science & Medicine (2023) Vol. 10, Iss. 2, pp. e001007-e001007
Open Access | Times Cited: 15
Deucravacitinib zeigt eine höhere Wirksamkeit und Sicherheit bei kutanem Lupus erythematodes im Vergleich zu verschiedenen Biologika und niedermolekularen Wirkstoffen: systematische Übersicht und Metaanalyse
Laura Bokor, Katalin Martyin, Máté Krebs, et al.
Kompass Autoimmun (2025), pp. 1-9
Closed Access
Cutaneous lupus erythematosus: A review of the literature
Stephanie Blake, Benjamin S. Daniel
International Journal of Women’s Dermatology (2019) Vol. 5, Iss. 5, pp. 320-329
Open Access | Times Cited: 40
Treatment of cutaneous lupus erythematosus: current approaches and future strategies
Hong Shi, Jóhann E. Guðjónsson, J. Michelle Kahlenberg
Current Opinion in Rheumatology (2020) Vol. 32, Iss. 3, pp. 208-214
Open Access | Times Cited: 38
Interventions for cutaneous disease in systemic lupus erythematosus
C Whitney Hannon, Collette McCourt, Hermenio Lima, et al.
Cochrane library (2021) Vol. 2021, Iss. 3
Open Access | Times Cited: 30
Clinical characteristics, treatment and outcome of subacute cutaneous lupus erythematosus induced by PD-1/PD-L1 inhibitors
Zhaoquan Wu, Rui Huang, Wei Sun, et al.
Archives of Dermatological Research (2024) Vol. 316, Iss. 10
Closed Access | Times Cited: 4
Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study
François Chasset, Laurent Arnaud, M. Jachiet, et al.
Journal of the American Academy of Dermatology (2017) Vol. 78, Iss. 1, pp. 107-114.e1
Closed Access | Times Cited: 35
<p>Lupus erythematosus tumidus: clinical perspectives</p>
Nikolaos Patsinakidis, Ocko Kautz, Bernhard F. Gibbs, et al.
Clinical Cosmetic and Investigational Dermatology (2019) Vol. Volume 12, pp. 707-719
Open Access | Times Cited: 33
Outcomes of Systemic Lupus Erythematosus in Patients who Discontinue Hydroxychloroquine
Zineb Aouhab, Hyun Sook Hong, Christopher Felicelli, et al.
ACR Open Rheumatology (2019) Vol. 1, Iss. 9, pp. 593-599
Open Access | Times Cited: 32
Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review
François Chasset, Camille Françès
Drugs (2019) Vol. 79, Iss. 11, pp. 1199-1215
Open Access | Times Cited: 31
Chilblains in immune-mediated inflammatory diseases: a review
Shirish Dubey, Nilay Joshi, Olivia Stevenson, et al.
Lara D. Veeken (2022) Vol. 61, Iss. 12, pp. 4631-4642
Open Access | Times Cited: 18
Plasmacytoid Dendritic Cells Are Not Major Producers of Type 1 IFN in Cutaneous Lupus: An In-Depth Immunoprofile of Subacute and Discoid Lupus
Thomas Vazquez, Jay Patel, Nilesh Kodali, et al.
Journal of Investigative Dermatology (2023) Vol. 144, Iss. 6, pp. 1262-1272.e7
Closed Access | Times Cited: 9
Advances in the pharmacological management of systemic lupus erythematosus
Alexander Tsoi, Dionysis Nikolopoulos, Ioannis Parodis
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 6, pp. 705-716
Open Access | Times Cited: 3
Advances in the treatment of systemic lupus erythematosus: From back to the future, to the future and beyond
Renaud Felten, Florence Scher, Jean Sibilia, et al.
Joint Bone Spine (2018) Vol. 86, Iss. 4, pp. 429-436
Open Access | Times Cited: 31
Hydroxychloroquine in dermatology: New perspectives on an old drug
Christopher Chew, Adrian Mar, Mandana Nikpour, et al.
Australasian Journal of Dermatology (2019) Vol. 61, Iss. 2
Open Access | Times Cited: 28
Lupus erythematosus: Significance of dermatologic findings
C. Lenormand, Dan Lipsker
Annales de Dermatologie et de Vénéréologie (2021) Vol. 148, Iss. 1, pp. 6-15
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top